Abivax S.A.: All-Time High After Successful Capital Increase and Solid Study Data
Reading Time: 3 minutes
Business Model: Abivax S.A. is a clinical biotechnology company developing therapeutics to regulate the immune system in inflammatory diseases. Market Entry Following Phase-3 Study Data: For the lead candidate Obefazimod for the treatment of chronic inflammatory bowel diseases, the FDA submission is expected to be filed in the fourth quarter following convincing study data. Funding Secured: At the beginning of July, the company completed a public offering totaling USD 920 million, ensuring liquidity until the fourth quarter of 2027. ...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
